Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Advaxis, Inc. - Common Stock (OP:ADXS)

0.2100 +0.0093 (+4.63%)

Streaming Delayed Price Updated: 11:30 AM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	686
Open	0.2007
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.2007
Today's Range	0.2100 - 0.2100
52wk Range	0.0270 - 0.8010
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

May 09, 2024

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

March 26, 2024

From Ayala Pharmaceuticals

Via GlobeNewswire

Performance

YTD	+165.5%	+165.5%
1 Month	+423.7%	+423.7%
3 Month	+530.6%	+530.6%
6 Month	+42.7%	+42.7%
1 Year	+600.0%	+600.0%

More News

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 20, 2024

From Ayala Pharmaceuticals

Via GlobeNewswire

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

February 06, 2024

From Immunome, Inc.

Via Business Wire

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

February 06, 2024

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

November 06, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

October 23, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

October 19, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 10, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

August 01, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

July 27, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

July 05, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

June 05, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 ↗

May 30, 2023

Via Benzinga

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 23, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors

March 08, 2023

Via News Direct

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

March 03, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

February 10, 2023

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ ↗

October 19, 2022

Via Benzinga

Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

October 19, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS

March 28, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 22, 2021

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 10, 2021

Via Benzinga

Frequently Asked Questions

Is Advaxis, Inc. - Common Stock publicly traded?

Yes, Advaxis, Inc. - Common Stock is publicly traded.

What exchange does Advaxis, Inc. - Common Stock trade on?

Advaxis, Inc. - Common Stock trades on the OTC Traded

What is the ticker symbol for Advaxis, Inc. - Common Stock?

The ticker symbol for Advaxis, Inc. - Common Stock is ADXS on the OTC Traded

What is the current price of Advaxis, Inc. - Common Stock?

The current price of Advaxis, Inc. - Common Stock is 0.2100

When was Advaxis, Inc. - Common Stock last traded?

The last trade of Advaxis, Inc. - Common Stock was at 01/09/26 11:30 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.